Merck (MRK) announced the start of construction for a $3B, 400,000-square-foot pharmaceutical manufacturing facility at its Elkton, Virginia, site. Merck’s investment in the Center of Excellence for Pharmaceutical Manufacturing is part of a more than $70B investment beginning in 2025 to expand domestic manufacturing and research and development – not including any future business development transactions in R&D – to drive its long-term growth and strengthen the status of the U.S. as a global leader in biopharmaceutical innovation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- IO Biotech reports expanded Cylembio results
- Merck announces KEYTRUDA, Padcev trial showed improvements in EFS
- Merck, Eisai announce follow-up data on KEYTRUDA plus LENVIMA
- Gilead, AstraZeneca, and Roche Data Signal New Growth in Cancer Drug Market
- Merck KGaA Joins Price Cut Agreement with Trump to Dodge Tariffs